Navigation Links
ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext US: ANX), announced today that it has completed patient enrollment in its bioequivalence study of ANX-514 (docetaxel emulsion for injection). The Company is on track to announce results from this study in the second quarter of 2009.

ANX-514 is a reformulation of the blockbuster chemotherapeutic agent, Taxotere(R), an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate, head and neck & gastric cancers. In 2007, the aggregate worldwide market for Taxotere was in excess of $3 billion.

The study is a multi-center, open-label, randomized two-period crossover comparison of ANX-514 and Taxotere, with a primary endpoint of pharmacokinetic equivalence of ANX-514 and Taxotere and a goal of 28 evaluable patients. The safety of a single dose of ANX-514 is being evaluated as a secondary endpoint. The U.S. Food and Drug Administration has indicated that this single study, should it demonstrate bioequivalence between ANX-514 and Taxotere, would provide sufficient human data to support the submission of an NDA.

About ANX-514 (docetaxel emulsion)

ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. In December 2008, the Company announced that it is exploring a range of strategic options, including the sale or disposition of one or more of its product candidate programs, a strategic business merger and other transactions that maximize the value of the Company's assets. More information can be found on ADVENTRX's web site at

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to consummate a strategic or partnering transaction or raise sufficient capital to fund the projects necessary to meet its goals, including funding the continued development and commercialization of ANX-530 or ANX-514; the risk that the Company's recent cost-cutting measures, as well as any future workforce reductions and/or reductions/delays in spending, will negatively impact the Company's development and commercialization plans, including its ability to achieve on time its previously stated goals; the risk that the departure of the Company's former Chief Executive Officer and President and Executive Vice President and Chief Financial Officer and/or ADVENTRX's leadership by a committee of executive officers will negatively impact ADVENTRX's ability to execute its business plan or to maintain effective disclosure controls and procedures or internal control over financial reporting; the risk that the bioequivalence study of ANX-514 does not demonstrate pharmacokinetic equivalence or bioequivalence; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-514, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-514; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings, including prior to the submission or the approval of an NDA for ANX-514; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data, including clinical investigators, expert data monitoring committees, contract laboratories and contract research organizations, may be substandard, or they may fail to perform as expected; the risk that ADVENTRX's stockholders will not approve a strategic or capital-raising transaction recommended by ADVENTRX's Board of Directors; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
2. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
3. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
5. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
7. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
8. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
9. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Post Your Comments:
(Date:12/1/2015)... Ohio , Dec. 1, 2015 ... to its GeneSight® Psychotropic test giving healthcare providers an ... medication decisions for patients suffering from depression, anxiety, ... other behavioral health conditions. i ... --> With the addition of two ...
(Date:12/1/2015)... 2015 --> ... "Nucleic Acid Labeling Market by Product (Reagents & Kits, ... In Vitro Transcription, Reverse Transcription, End Labeling), by Region ... global market is expected to reach USD 1,925.7 Million ... at a CAGR of 8.65%. Browse 77 ...
(Date:12/1/2015)... , Dec. 01, 2015 ... the "Veterinary Equipment and Disposables Market by ... report to their offering. --> ... "Veterinary Equipment and Disposables Market by product, ... report to their offering. --> Research ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December 1, ... fixed price per sprint agile development contract to support the National Geospatial-Intelligence Agency's ... years, provides software engineering, infrastructure, as well as operations and sustainment support to ...
(Date:12/1/2015)... Auburn, CA (PRWEB) , ... December 01, 2015 ... ... software and clinical solutions for the care management and population health arenas, is ... on providing clinical and cost containment services, has successfully implemented the ACUITY Complete ...
(Date:12/1/2015)... Park, CA (PRWEB) , ... December 01, 2015 , ... ... (XTC) has selected 10 semi-finalists to head to Las Vegas for CES 2016, the ... judges including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments ...
(Date:12/1/2015)... ... , ... With FCPX Overlay: Grit , users can apply a grit ... are truly endless, all with a click of a mouse. Each user has full ... depth of field and more, all within Final Cut Pro X. , With FCPX ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... as a Modern Man for 2015. , Angeleno Magazine is a division ... States. Established in 1994, Modern Luxury includes more than 50 magazine titles across ...
Breaking Medicine News(10 mins):